A Phase 2 interventional study of Pemetrexed in Cervical Intraepithelial Neoplasia, Uterine Neoplasms and Genital Neoplasms, Female, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2009-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Uterine Cervical Dysplasia with a site in United States — 10 open to participants now, 14 under way, none of them phase 3. Uterine Cervical Dysplasia · United States.
Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, this one is the 60th largest by enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2005, is one of 25 in phase 2, and was the 17th registered.
410 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
Browse Uterine Cervical Dysplasia studies →10 of the 109 studies in Uterine Cervical Dysplasia with a site in United States are open now. Recruiting first, the newest first:
PapiVax Biotech, Inc. · Sites in United States, Taiwan
Ages 18–60 · Women only
Lindsay Ferguson, MD · Sites in United States
Ages 18+ · Women only
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
Northwell Health · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 14 · Phase 4 2
First in 1993; this study’s year is marked. 7 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.
Median enrollment 80 across the 86 interventional studies, 250 across the 21 observational. Of the 83 that completed or were terminated, 27 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 109 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 1 study filed under Uterine Cervical Dysplasia — fewer than ten, so there is no comparison to draw.
4 of the studies in Uterine Cervical Dysplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191133Lindsay Ferguson, MDFenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | 2026-12-30 |
| NCT04712851Jonsson Comprehensive Cancer CenterPembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | 2027-01-31 |
| NCT05051722Mayo ClinicLeveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | 2027-07-30 |
| NCT07520188UNC Lineberger Comprehensive Cancer CenterC-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed
Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Time frame: baseline to measured progressive disease (up to 5 years)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: time of initial response until documented tumor progression (up to 5 years)
Progression-Free Survival
The period from study entry until disease progression, death or date of last contact.
Time frame: baseline until documented tumor progression (up to 5 years)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline until death from any cause (up to 5 years)
| Milestone | Pemetrexed |
|---|---|
| Started | 29 |
| Completed | 27 |
| Not completed | 2 |
| Withdrew: Inevaluable (never treated) | 2 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
| participants | Pemetrexed |
|---|---|
| Complete Response | 0 |
| Partial Response | 4 |
| Stable Disease | 16 |
| Disease Progression | 7 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | Pemetrexed |
|---|---|
| Duration of Response | 4.4 (4.2 to 33.7) |
The period from study entry until disease progression, death or date of last contact.
| months | Pemetrexed |
|---|---|
| Progression-Free Survival | 3.1 (0.9 to 23.7) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| months | Pemetrexed |
|---|---|
| Overall Survival | 7.4 (1.4 to 23.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | — | — |
| Event | Pemetrexed |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/27 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/27 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/27 |
| PyelonephritisInfections and infestations | 1/27 |
| Blood alkaline phosphatase increasedInvestigations | 1/27 |
| Haemoglobin decreasedInvestigations | 1/27 |
| White blood cell count decreasedInvestigations | 1/27 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/27 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/27 |
| Female genital tract fistulaReproductive system and breast disorders | 1/27 |
| Event | Pemetrexed |
|---|---|
| AnemiaBlood and lymphatic system disorders | 23/27 |
| ConstitutionalGeneral disorders | 21/27 |
| MetabolicMetabolism and nutrition disorders | 20/27 |
| LeukopeniaBlood and lymphatic system disorders | 19/27 |
| NeutropeniaBlood and lymphatic system disorders | 17/27 |
| GastrointestinalGastrointestinal disorders | 16/27 |
| Nausea/vomitingGastrointestinal disorders | 13/27 |
| PainGeneral disorders | 12/27 |
| InfectionInfections and infestations | 12/27 |
| Alkaline phosphataseInvestigations | 11/27 |
| Age, Customized(participants) | Pemetrexed |
|---|---|
| <40 years | 6 |
| 40-49 years | 9 |
| 50-59 years | 7 |
| 60-69 years | 4 |
| >69 years | 1 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 27 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Pemetrexed |
|---|---|
| White | 24 |
| Black | 2 |
| Asian | 1 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| United States | 27 |
| Cell Type(participants) | Pemetrexed |
|---|---|
| Squamous | 19 |
| Adenocarcinoma | 6 |
| Clear cell | 1 |
| Adenosquamous | 1 |
| Gynecologic Oncology Group (GOG) Performance Status(participants) | Pemetrexed |
|---|---|
| 0 - Fully active | 16 |
| 1 - Ambulatory, Restricted Strenuous Activity | 9 |
| 2 - Ambulatory, No Work Activities | 2 |
| Prior Therapy(participants) | Pemetrexed |
|---|---|
| Prior Chemotherapy | 27 |
| No Prior Chemotherapy | 0 |
| Prior Radiotherapy | 23 |
| No Prior Radiotherapy | 4 |
| Tumor Grade(participants) | Pemetrexed |
|---|---|
| G1 - Well-Differentiated | 5 |
| G2 - Moderately Differentiated | 15 |
| G3 - Poorly Differentiated | 5 |
| Unspecified | 2 |
The record gives a start of Feb 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed